Full Title of Trial: "Clinical Field Study to Evaluate the Effectiveness and Safety of Torsemide Compared to Furosemide for the Treatment of Pulmonary Edema Related to Congestive Heart Failure in Dogs"
Trial Description: This trial aims to evaluate the safety and effectiveness of a novel diuretic medication, torsemide, compared to furosemide for the treatment of pulmonary edema related to congestive heart failure in dogs with chronic valvular heart disease (CVHD) or dilated cardiomyopathy (DCM).
An initial visit including physical examination, clinical pulmonary edema score, echocardiogram, blood pressure, thoracic radiographs, urine and blood sampling will be performed. Dogs will be randomly assigned to receive Torsemide or Furosemide every day for 84 days as directed. Owners and clinicians will be unaware whether the dog is receiving Torsemide or Furosemide. Physical exams, clinical pulmonary clinical score and blood samplings will be repeated 5, 14, 28, 56, and 84 days after the initial visit. The thoracic radiographs will be repeated 14 and 84 days after the initial visit.
Eligibility
- Dog is newly diagnosed with congestive heart failure, Stage C
- Dogs must be presenting with clinical and radiographic signs of pulmonary edema
- Dogs may be newly diagnosed cases not currently receiving medication
- Dogs previously diagnosed but not currently receiving diuretic treatment
The sponsor will pay for the cost of all examinations and tests for the duration of the study and provide the study medication to be used during the trial. If your dog has any adverse events that are study related and require treatment, the Sponsor will cover the costs of reasonable treatment. In return for your dog’s enrollment and your participation in the study, you will be eligible to receive a $500 credit toward your hospital bill.
For more information, please contact the study coordinator, June Chiango, at 215-573-6610 or email at jchiango@upenn.edu.